JP2014534236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534236A5 JP2014534236A5 JP2014541272A JP2014541272A JP2014534236A5 JP 2014534236 A5 JP2014534236 A5 JP 2014534236A5 JP 2014541272 A JP2014541272 A JP 2014541272A JP 2014541272 A JP2014541272 A JP 2014541272A JP 2014534236 A5 JP2014534236 A5 JP 2014534236A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- acceptable salt
- pharmaceutically acceptable
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 83
- 239000002904 solvent Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 16
- 239000007800 oxidant agent Substances 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims 28
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims 8
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 239000002585 base Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000014461 Ataxins Human genes 0.000 claims 1
- 108010078286 Ataxins Proteins 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010013883 Dwarfism Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
- 208000008955 Mucolipidoses Diseases 0.000 claims 1
- 206010072928 Mucolipidosis type II Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000005660 Protein C Deficiency Diseases 0.000 claims 1
- 208000021811 Sandhoff disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- -1 anti-infectives Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229910000000 metal hydroxide Inorganic materials 0.000 claims 1
- 150000004692 metal hydroxides Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 208000000638 myeloperoxidase deficiency Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 description 6
- 0 *C(C[n](c(C(*)(*)*)c1)c(cc2*)c1cc2NC(C(C1(*)*)(C1(*)I)c1cc(*)c(*)cc1)=O)CO Chemical compound *C(C[n](c(C(*)(*)*)c1)c(cc2*)c1cc2NC(C(C1(*)*)(C1(*)I)c1cc(*)c(*)cc1)=O)CO 0.000 description 5
- YZMJWDVWMSBXMZ-UHFFFAOYSA-N CC(C)(C(O)=O)c1cc(cc(c(F)c2)NC(C3(CC3)c(cc3O4)ccc3OC4(F)F)=O)c2[n]1CC(CO)O Chemical compound CC(C)(C(O)=O)c1cc(cc(c(F)c2)NC(C3(CC3)c(cc3O4)ccc3OC4(F)F)=O)c2[n]1CC(CO)O YZMJWDVWMSBXMZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557043P | 2011-11-08 | 2011-11-08 | |
| US61/557,043 | 2011-11-08 | ||
| US201261610257P | 2012-03-13 | 2012-03-13 | |
| US61/610,257 | 2012-03-13 | ||
| PCT/US2012/064217 WO2013070961A1 (en) | 2011-11-08 | 2012-11-08 | Modulators of atp-binding cassette transporters |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534236A JP2014534236A (ja) | 2014-12-18 |
| JP2014534236A5 true JP2014534236A5 (enExample) | 2015-12-24 |
| JP6072056B2 JP6072056B2 (ja) | 2017-02-01 |
Family
ID=47278514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541272A Active JP6072056B2 (ja) | 2011-11-08 | 2012-11-08 | Ａｔｐ−結合カセットトランスポーターの修飾因子 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9254291B2 (enExample) |
| EP (1) | EP2776427B1 (enExample) |
| JP (1) | JP6072056B2 (enExample) |
| KR (1) | KR101985044B1 (enExample) |
| CN (1) | CN104039775B (enExample) |
| AU (1) | AU2012335714B2 (enExample) |
| CA (1) | CA2852991C (enExample) |
| ES (1) | ES2622154T3 (enExample) |
| HR (1) | HRP20170458T1 (enExample) |
| IL (1) | IL232308A (enExample) |
| IN (1) | IN2014KN00885A (enExample) |
| LT (1) | LT2776427T (enExample) |
| ME (1) | ME02650B (enExample) |
| MX (1) | MX357328B (enExample) |
| RU (1) | RU2640420C2 (enExample) |
| SI (1) | SI2776427T1 (enExample) |
| WO (1) | WO2013070961A1 (enExample) |
| ZA (1) | ZA201403262B (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
| MX2008002019A (es) | 2005-08-11 | 2008-04-16 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
| ES2778846T3 (es) | 2005-11-08 | 2020-08-12 | Vertex Pharma | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| AU2006336504C9 (en) | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| NZ596889A (en) | 2006-04-07 | 2013-06-28 | Vertex Pharma | Use of amide indole derivatives as modulators of ATP-binding cassette transporters |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| CN102863432B (zh) | 2007-05-09 | 2016-09-07 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| HUE028426T2 (en) | 2007-08-24 | 2016-12-28 | Vertex Pharma | Isothiazolopyridinones for (inter alia) treating cystic fibrosis |
| ES2556080T3 (es) | 2007-11-16 | 2016-01-12 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de unión a ATP |
| WO2009076142A2 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| KR20150063170A (ko) | 2007-12-07 | 2015-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| EA201070699A1 (ru) * | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CN106432213A (zh) | 2008-02-28 | 2017-02-22 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
| EP2615085B1 (en) | 2008-03-31 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as CFTR modulators |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| AU2009296271A1 (en) * | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| MX384179B (es) | 2009-03-20 | 2025-03-14 | Vertex Pharma | Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística. |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
| CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| RU2745977C2 (ru) * | 2010-04-22 | 2021-04-05 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| KR101985044B1 (ko) | 2011-11-08 | 2019-05-31 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송체의 조절제 |
| DK2806859T3 (da) | 2012-01-25 | 2019-08-05 | Vertex Pharma | Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| DK3068392T5 (da) | 2013-11-12 | 2021-09-20 | Vertex Pharma | Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme |
| SG10201913575VA (en) | 2014-04-15 | 2020-02-27 | Vertex Pharma | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| EP3798214B1 (en) | 2014-10-06 | 2022-09-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016081556A1 (en) | 2014-11-18 | 2016-05-26 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
| EP3240539A4 (en) | 2014-12-31 | 2018-07-25 | Auspex Pharmaceuticals, Inc. | Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016160945A1 (en) | 2015-03-31 | 2016-10-06 | Concert Pharmaceuticals, Inc. | Deuterated vx-661 |
| CN105130949B (zh) * | 2015-09-02 | 2019-01-29 | 阜新奥瑞凯新材料有限公司 | 1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙基腈的制备方法 |
| CN105218510B (zh) * | 2015-10-23 | 2017-09-15 | 上海平创化工科技有限公司 | 一种2,2‑二氟‑5‑氯甲基胡椒环的制备方法 |
| US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
| SG10201913595YA (en) | 2016-09-30 | 2020-02-27 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| MA49235B1 (fr) | 2016-12-09 | 2021-02-26 | Vertex Pharma | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| EP3634402B1 (en) | 2017-06-08 | 2026-01-21 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| IL273831B2 (en) | 2017-10-19 | 2024-10-01 | Vertex Pharma | Crystalline forms and compositions of cftr modulators |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3752510B1 (en) | 2018-02-15 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CA3188787A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| KR20250122428A (ko) * | 2024-02-06 | 2025-08-13 | 케이디바이오 주식회사 | Abcg 수송체 활성화제를 포함하는 항바이러스 조성물 및 이의 이용 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6426331B1 (en) | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
| DE60045564D1 (de) | 1999-02-24 | 2011-03-03 | Hoffmann La Roche | 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| AU2002258794A1 (en) | 2001-04-10 | 2003-10-20 | Transtech Pharma, Inc. | Probes, systems and methods for drug discovery |
| JP4977319B2 (ja) | 2002-09-30 | 2012-07-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 嚢胞性線維症膜コンダクタンス制御因子蛋白質阻害薬およびその使用方法 |
| US20050113423A1 (en) | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
| EP3345895B1 (en) | 2003-04-11 | 2019-12-04 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
| US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| EP1646615B1 (en) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| EP1638505B1 (en) | 2003-06-27 | 2012-04-25 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Amphiphilic pyridinium compounds, method of making and use thereof |
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| AU2004279855A1 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
| EP1682127B1 (en) | 2003-11-14 | 2009-07-29 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
| JP4960708B2 (ja) | 2004-01-30 | 2012-06-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセットトランスポーターのモジュレーター |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| AU2005228685B2 (en) | 2004-03-30 | 2010-08-19 | The Regents Of The University Of California | Hydrazide-containing CFTR inhibitor compounds and uses thereof |
| AU2005249154B2 (en) | 2004-06-01 | 2011-02-10 | Luminex Molecular Diagnostics, Inc. | Method of detecting cystic fibrosis associated mutations |
| AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
| WO2006044456A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| EP1865949B1 (en) | 2005-03-11 | 2012-11-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| CA2603402C (en) | 2005-04-08 | 2017-10-31 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| JP5426878B2 (ja) | 2005-05-24 | 2014-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ−結合カセットトランスポーターのモジュレーター |
| MX2008002019A (es) | 2005-08-11 | 2008-04-16 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
| CN101312722A (zh) | 2005-10-06 | 2008-11-26 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| ES2778846T3 (es) | 2005-11-08 | 2020-08-12 | Vertex Pharma | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| EP1979367A2 (en) | 2005-12-24 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Quinolin-4-one derivatives as modulators of abc transporters |
| EP1974212A1 (en) | 2005-12-27 | 2008-10-01 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| AU2006336504C9 (en) | 2005-12-28 | 2015-05-14 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| NZ596889A (en) | 2006-04-07 | 2013-06-28 | Vertex Pharma | Use of amide indole derivatives as modulators of ATP-binding cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| ES2377840T3 (es) | 2006-05-12 | 2012-04-02 | Vertex Pharmaceuticals, Inc. | Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| HUE034579T2 (en) | 2006-11-03 | 2018-02-28 | Vertex Pharma | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| CN102863432B (zh) | 2007-05-09 | 2016-09-07 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| HUE025553T2 (en) | 2007-05-25 | 2016-02-29 | Vertex Pharma | CFTR modulators |
| WO2009023509A2 (en) | 2007-08-09 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Therapeutic combinations useful in treating cftr related diseases |
| HUE028426T2 (en) | 2007-08-24 | 2016-12-28 | Vertex Pharma | Isothiazolopyridinones for (inter alia) treating cystic fibrosis |
| RU2010114732A (ru) | 2007-09-14 | 2011-10-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида |
| CN101821266B (zh) | 2007-09-14 | 2014-03-12 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
| ES2556080T3 (es) | 2007-11-16 | 2016-01-12 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de unión a ATP |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| KR20150063170A (ko) | 2007-12-07 | 2015-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| WO2009076142A2 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| EA201070699A1 (ru) | 2007-12-07 | 2011-02-28 | Вертекс Фармасьютикалз Инкорпорейтед | Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты |
| WO2009076593A1 (en) | 2007-12-13 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN106432213A (zh) | 2008-02-28 | 2017-02-22 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
| EP2615085B1 (en) | 2008-03-31 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as CFTR modulators |
| LT3345625T (lt) | 2008-08-13 | 2021-02-10 | Vertex Pharmaceuticals Incorporated | Farmacinė kompozicija ir jos vartojimas |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| AU2009296271A1 (en) | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| AU2009308232B2 (en) | 2008-10-23 | 2016-02-04 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
| DK2358680T3 (da) | 2008-10-23 | 2013-06-24 | Vertex Pharma | Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid |
| NZ592685A (en) | 2008-10-23 | 2013-04-26 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| HRP20150288T1 (hr) * | 2008-11-06 | 2015-04-24 | Vertex Pharmaceuticals Incorporated | Modulatori atp-vezujuä†ih kasetnih transportera |
| US8367660B2 (en) | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX384179B (es) | 2009-03-20 | 2025-03-14 | Vertex Pharma | Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística. |
| HUE038854T2 (hu) | 2009-03-20 | 2018-12-28 | Vertex Pharma | Cisztás fibrózis transzmembrán konduktancia regulátor modulátorai |
| CA2772792A1 (en) | 2009-09-17 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Process for preparing azabicyclic compounds |
| EP2813227A1 (en) | 2009-10-22 | 2014-12-17 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| UA108087C2 (uk) | 2009-10-23 | 2015-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду |
| KR20120104554A (ko) | 2009-10-23 | 2012-09-21 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
| CN103180298A (zh) | 2010-03-19 | 2013-06-26 | 沃泰克斯药物股份有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟基苯基]-1,4-二氢-4-氧代喹啉-3-甲酰胺的固体形式 |
| SMT202100051T1 (it) | 2010-03-25 | 2021-03-15 | Vertex Pharma | Dispersione solida di una forma amorfa di (r)-1-(2,2-difluorobenzo[d][1,3]diossol-5-il)-n-(1-(2,3-diidrossipropil)-6-fluoro-2-(1-idrossi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropan-carbossamide |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
| CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| NZ603044A (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| RU2745977C2 (ru) * | 2010-04-22 | 2021-04-05 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| AU2011242452A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| WO2011133953A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| AR081920A1 (es) | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
| CA2798412A1 (en) | 2010-05-20 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
| CA2809263A1 (en) | 2010-08-27 | 2012-03-01 | Eleni Dokou | Pharmaceutical composition and administrations thereof |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| AU2012332225A1 (en) | 2011-11-02 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases |
| KR101985044B1 (ko) | 2011-11-08 | 2019-05-31 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송체의 조절제 |
| DK2806859T3 (da) | 2012-01-25 | 2019-08-05 | Vertex Pharma | Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| SMT202500078T1 (it) | 2012-11-02 | 2025-03-12 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
-
2012
- 2012-11-08 KR KR1020147014913A patent/KR101985044B1/ko active Active
- 2012-11-08 LT LTEP12794811.5T patent/LT2776427T/lt unknown
- 2012-11-08 ME MEP-2017-72A patent/ME02650B/me unknown
- 2012-11-08 CN CN201280054919.8A patent/CN104039775B/zh active Active
- 2012-11-08 SI SI201230931A patent/SI2776427T1/sl unknown
- 2012-11-08 RU RU2014123381A patent/RU2640420C2/ru active
- 2012-11-08 ES ES12794811.5T patent/ES2622154T3/es active Active
- 2012-11-08 EP EP12794811.5A patent/EP2776427B1/en active Active
- 2012-11-08 JP JP2014541272A patent/JP6072056B2/ja active Active
- 2012-11-08 MX MX2014005462A patent/MX357328B/es active IP Right Grant
- 2012-11-08 CA CA2852991A patent/CA2852991C/en active Active
- 2012-11-08 IN IN885KON2014 patent/IN2014KN00885A/en unknown
- 2012-11-08 HR HRP20170458TT patent/HRP20170458T1/hr unknown
- 2012-11-08 US US13/672,538 patent/US9254291B2/en active Active
- 2012-11-08 AU AU2012335714A patent/AU2012335714B2/en active Active
- 2012-11-08 WO PCT/US2012/064217 patent/WO2013070961A1/en not_active Ceased
-
2014
- 2014-04-28 IL IL232308A patent/IL232308A/en active IP Right Grant
- 2014-05-06 ZA ZA2014/03262A patent/ZA201403262B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534236A5 (enExample) | ||
| RU2014123381A (ru) | Модуляторы транспортеров атф-связывающей кассеты | |
| JP2012521362A5 (enExample) | ||
| JP2011513321A5 (enExample) | ||
| RU2015153068A (ru) | ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА | |
| EP3004053B1 (en) | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities | |
| RU2010114732A (ru) | Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида | |
| RU2011122646A (ru) | Модуляторы переносчиков атф-связывающих кассет | |
| JP2011516420A5 (enExample) | ||
| US20180297946A1 (en) | Polymorphic form of pyrrole derivative and intermediate thereof | |
| JP2010528050A5 (enExample) | ||
| US6541668B1 (en) | Methods for preparing 3-arloxy-3-arylpropylamines and intermediates thereof | |
| HRP20160682T1 (hr) | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline | |
| JP2007519740A5 (enExample) | ||
| US20200290971A1 (en) | Deuterated cftr potentiators | |
| JP2011505338A5 (enExample) | ||
| IL273752B2 (en) | Ingredients, compounds and methods for increasing CFTR activity | |
| Zhu et al. | Catalyst: and solvent-free synthesis of imidazo [1, 2-a] pyridines | |
| US10112898B2 (en) | Process for the preparation of saroglitazar pharmaceutical salts | |
| JP2012514038A5 (enExample) | ||
| JP2013536231A5 (enExample) | ||
| ME02105B (me) | Modulatori atp-vezujucih kasetnih transportera | |
| JP2013508407A5 (enExample) | ||
| JP2010526814A5 (enExample) | ||
| RU2008144124A (ru) | Модуляторы атф-связывающих кассетных транспортеров |